
    
      Eligible participants will be randomized to 1 of the following 2 treatment arms:

        1. Budesonide MMX 9 mg (1 tablet)

        2. Placebo (tablet indistinguishable from budesonide MMX 9 mg tablet)

      The assigned study drug will be taken as a single oral tablet each morning after breakfast.
      In addition to the study drug, all participants will continue their existing background oral
      5-ASA regimen during the treatment period.
    
  